Compare CVS Health Corp (CVS) vs Schwab US Dividend Equity ETF (SCHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Schwab US Dividend Equity ETF — how do they compare? CVS Health Corp trades at $93.65 (market cap $122.36B), while Schwab US Dividend Equity ETF trades at $34.28. The key difference: CVS Health Corp pays a 2.78% dividend while Schwab US Dividend Equity ETF pays none, and Schwab US Dividend Equity ETF is trading nearer its 52-week high, CVS Health Corp nearer its low. Which is the better fit depends on your goals.
| CVS | SCHD | |
|---|---|---|
Market Cap | $122.36B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $110.60 | $34.27 |
52-Week Low | $65.51 | $26.44 |
Enterprise Value | $184.71B | — |
Dividend Yield | 2.78% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $95.70, down 0.54% on the day, with a bearish technical signal and key support at $95. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.58 versus $1.87 expected, and raised its full-year guidance. Revenue growth remains robust, reaching $402.07 billion in 2025, though net income margin compressed to 1.18%. Analyst sentiment is overwhelmingly positive with a consensus price target of $115.00.
The outlook for CVS is cautiously optimistic, driven by operational improvements in its Aetna segment and raised cash flow guidance. Investment opportunities include potential upside to the consensus target, but risks involve margin pressures, regulatory changes impacting pharmacy benefits in 2027, and high debt levels. The stock's current valuation at a P/E of 25.25 may limit near-term gains if earnings growth slows.
SCHD, the Schwab U.S. Dividend Equity ETF, trades at $33.90, up 0.59% today, with a bullish technical signal from moving averages and neutral oscillators. The ETF focuses on high-quality U.S. dividend-paying stocks, offering income stability. Recent news highlights its popularity among retirees for generating passive income, with institutional buying activity noted in Q2 2026 filings.
The outlook for SCHD remains positive for income-focused investors, leveraging dividend growth and low costs. Risks include interest rate sensitivity and market volatility affecting dividend stocks. Analyst sentiment is generally favorable, emphasizing its role in diversified retirement portfolios.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Schwab US Dividend Equity ETF
SCHD is an ETF that tracks the Dow Jones U.S. Dividend 100 Index. It selects high-quality companies with a consistent track record of paying dividends, focusing on financial strength metrics like cash flow to total debt and return on equity, and excluding REITs. The fund aims to provide both income and capital appreciation, making it a popular choice for long-term, dividend-focused investors.
Read more on SCHD →
